Covered recipient · General Payments record
ABHIJEET KUMAR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$45,295.95
54 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,780.00 | 9 |
| Travel and Lodging | $5,009.82 | 23 |
| Consulting Fee | $1,500.00 | 1 |
| Food and Beverage | $1,006.13 | 21 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $28,119.38 | 31 |
| AstraZeneca Pharmaceuticals LP | $14,141.19 | 10 |
| ABBVIE INC. | $2,958.94 | 9 |
| PFIZER INC. | $33.76 | 2 |
| Geron Corporation | $22.68 | 1 |
| Tempus AI, Inc | $20.00 | 1 |
Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ABHIJEET KUMAR
NPI 1134409923 · CMS profile ID 2786418
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BALTIMORE, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
54 matching records · $45,295.95 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–54 of 54.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Tempus AI, Inc | $20.00 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250347906 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.28 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206842997 | CMS |
| Geron Corporation | $22.68 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238890286 | CMS |
| PFIZER INC. | $18.29 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230213305 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $393,692.84 | 168 |
| PY2024 | Principal investigator | $567,698.85 | 161 |
| PY2023 | Principal investigator | $382,710.87 | 143 |
| PY2022 | Principal investigator | $306,571.10 | 127 |
| PY2021 | Principal investigator | $82,080.35 | 60 |
| PY2020 | Principal investigator | $218,560.38 | 143 |
| PY2019 | Principal investigator | $163,209.44 | 87 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
168 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity NORTH CAMPUS PHARMACY RECIEVING | A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies | No dispute reported | 06/30/2026 | 1202535275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,641.70 | 12/19/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184278810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,288.70 | 12/19/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184278812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.00 | 12/11/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184274262 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $910.00 | 12/11/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184274264 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,430.00 | 12/09/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328889 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,516.00 | 12/09/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333086 |
| Principal investigator 1 | ABBVIE INC. | $3,413.59 | 12/08/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529664 |
| Principal investigator 1 | Epizyme, Inc. | $999.50 | 12/08/2025 | Non-covered Recipient Entity University Arizona Cancer Ctr | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282753 |
| Principal investigator 1 | Epizyme, Inc. | $1,000.00 | 12/08/2025 | Non-covered Recipient Entity University Arizona Cancer Ctr | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282755 |
| Principal investigator 1 | Epizyme, Inc. | $1,250.00 | 12/08/2025 | Non-covered Recipient Entity University Arizona Cancer Ctr | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282757 |
| Principal investigator 1 | ABBVIE INC. | $539.50 | 12/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202528106 |
| Principal investigator 1 | ABBVIE INC. | $1,144.00 | 12/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202526240 |
| Principal investigator 1 | ABBVIE INC. | $3,413.59 | 11/25/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202525392 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,430.00 | 11/25/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,515.50 | 11/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184263407 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,170.00 | 11/18/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328885 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $975.00 | 11/18/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328887 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $975.00 | 11/18/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328893 |
| Principal investigator 1 | ABBVIE INC. | $4,420.00 | 11/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202520105 |
| Principal investigator 1 | ABBVIE INC. | $52.00 | 10/31/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202519961 |
| Principal investigator 1 | Epizyme, Inc. | $128.70 | 10/31/2025 | Non-covered Recipient Entity University Arizona Cancer Ctr | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282749 |
| Principal investigator 1 | ABBVIE INC. | $2,470.00 | 10/30/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202519827 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 10/28/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202518815 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,720.00 | 10/28/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333082 |
| Principal investigator 1 | ABBVIE INC. | $1,755.00 | 10/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202518397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.50 | 10/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184252464 |
| Principal investigator 1 | ABBVIE INC. | $39,355.61 | 10/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202518185 |
| Principal investigator 1 | ABBVIE INC. | $1,105.00 | 10/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202517453 |
| Principal investigator 1 | Epizyme, Inc. | $850.00 | 10/20/2025 | Non-covered Recipient Entity University Arizona Cancer Ctr | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184282751 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,264.60 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184248856 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,641.70 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184248858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,268.60 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184248860 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,488.20 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184244525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,112.20 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184244527 |
| Principal investigator 1 | ABBVIE INC. | $5,560.94 | 09/29/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202512774 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,106.00 | 09/23/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71.50 | 09/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184241884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,641.70 | 09/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184241886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,268.60 | 09/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184241888 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 09/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202511490 |
| Principal investigator 1 | ABBVIE INC. | $1,287.00 | 09/16/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202511038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,024.50 | 09/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184236866 |
| Principal investigator 1 | Epizyme, Inc. | $1,630.00 | 09/11/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284548 |
| Principal investigator 1 | Epizyme, Inc. | $750.00 | 09/04/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284542 |
| Principal investigator 1 | Epizyme, Inc. | $1,000.00 | 09/04/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284544 |
| Principal investigator 1 | Epizyme, Inc. | $1,200.00 | 09/04/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284546 |
| Principal investigator 1 | Epizyme, Inc. | $4,986.25 | 09/04/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284550 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 09/02/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202506947 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $12,596.00 | 09/02/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328895 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,210.00 | 09/02/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328897 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,170.00 | 09/02/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190328899 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 08/28/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202506429 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 08/26/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202505855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 08/26/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184230577 |
| Principal investigator 1 | Epizyme, Inc. | $250.00 | 08/22/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284538 |
| Principal investigator 1 | Epizyme, Inc. | $593.75 | 08/22/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284540 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,109.30 | 08/21/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184229891 |
| Principal investigator 1 | ABBVIE INC. | $1,144.00 | 08/15/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202504983 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184228569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,437.90 | 08/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184226477 |
| Principal investigator 1 | ABBVIE INC. | $1,755.00 | 07/30/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202500522 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,973.00 | 07/29/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333074 |
| Principal investigator 1 | Epizyme, Inc. | $125.00 | 07/18/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284536 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 07/17/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202498746 |
| Principal investigator 1 | ABBVIE INC. | $1,105.00 | 07/15/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202498310 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 07/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202497654 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,840.00 | 07/07/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190333077 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $130.00 | 07/06/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $910.00 | 07/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184212717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.00 | 07/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184212719 |
| Principal investigator 1 | ABBVIE INC. | $2,170.69 | 07/02/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202496217 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $260.00 | 06/20/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,221.10 | 06/19/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184209380 |
| Principal investigator 1 | ABBVIE INC. | $845.00 | 06/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202492227 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 06/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202492235 |
| Principal investigator 1 | ABBVIE INC. | $3,584.81 | 06/17/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202491815 |
| Principal investigator 1 | ABBVIE INC. | $2,470.00 | 06/17/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202491817 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 06/17/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202491821 |
| Principal investigator 1 | ABBVIE INC. | $507.00 | 06/17/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202491823 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,860.00 | 06/17/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331579 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $175.00 | 06/17/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,502.30 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184204469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184204471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184204473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,900.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184204475 |
| Principal investigator 1 | ABBVIE INC. | $4,485.00 | 06/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202488975 |
| Principal investigator 1 | ABBVIE INC. | $4,191.88 | 06/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202488977 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $9,842.99 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190326016 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $780.00 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331581 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,210.00 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331583 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $975.00 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331587 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $390.00 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331589 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $455.00 | 05/30/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190331591 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 05/29/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202487075 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $390.00 | 05/29/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804232 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $260.00 | 05/29/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804234 |
| Principal investigator 1 | ABBVIE INC. | $819.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486031 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $752.65 | 05/09/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804228 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040.00 | 05/09/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804230 |
| Principal investigator 1 | ABBVIE INC. | $249.60 | 05/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202481089 |
| Principal investigator 1 | ABBVIE INC. | $1,924.00 | 04/25/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202479569 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479125 |
| Principal investigator 1 | ABBVIE INC. | $325.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202479129 |
| Principal investigator 1 | ABBVIE INC. | $845.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202479134 |
| Principal investigator 1 | ABBVIE INC. | $123.50 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479139 |
| Principal investigator 1 | ABBVIE INC. | $975.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479158 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479162 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202479166 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479170 |
| Principal investigator 1 | ABBVIE INC. | $1,144.00 | 04/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202478779 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $780.00 | 04/20/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804226 |
| Principal investigator 1 | ABBVIE INC. | $1,828.79 | 04/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202471957 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,170.00 | 04/01/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804224 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 03/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202466733 |
| Principal investigator 1 | ABBVIE INC. | $325.00 | 03/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202466981 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 03/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202465008 |
| Principal investigator 1 | ABBVIE INC. | $507.00 | 03/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202465034 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 03/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202465065 |
| Principal investigator 1 | Epizyme, Inc. | $250.00 | 03/13/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284534 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,430.00 | 03/11/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190325868 |
| Principal investigator 1 | ABBVIE INC. | $5,056.38 | 03/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202459975 |
| Principal investigator 1 | ABBVIE INC. | $10,199.38 | 03/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202462164 |
| Principal investigator 1 | BeiGene USA, Inc. | $302.00 | 03/04/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190324570 |
| Principal investigator 1 | BeiGene USA, Inc. | $390.00 | 03/04/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190325870 |
| Principal investigator 1 | BeiGene USA, Inc. | $780.00 | 03/04/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190325872 |
| Principal investigator 1 | Epizyme, Inc. | $125.00 | 03/04/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284532 |
| Principal investigator 1 | Genmab BV | $3,120.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937496 |
| Principal investigator 1 | Genmab BV | $3,900.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937499 |
| Principal investigator 1 | Genmab BV | $2,340.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937502 |
| Principal investigator 1 | Genmab BV | $2,600.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937506 |
| Principal investigator 1 | Genmab BV | $520.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937510 |
| Principal investigator 1 | Genmab BV | $3,200.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937512 |
| Principal investigator 1 | Genmab BV | $2,600.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937516 |
| Principal investigator 1 | Genmab BV | $1,200.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937520 |
| Principal investigator 1 | Genmab BV | $1,300.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937523 |
| Principal investigator 1 | Genmab BV | $2,600.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937526 |
| Principal investigator 1 | Genmab BV | $2,600.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937529 |
| Principal investigator 1 | Genmab BV | $3,240.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. | No dispute reported | 06/30/2026 | 1235937533 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 02/26/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202454069 |
| Principal investigator 1 | ABBVIE INC. | $1,040.00 | 02/26/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202454087 |
| Principal investigator 1 | BeiGene USA, Inc. | $9,516.00 | 02/25/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190324572 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 02/21/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202453581 |
| Principal investigator 1 | ABBVIE INC. | $325.00 | 02/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202453187 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $390.00 | 02/19/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804220 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $975.00 | 02/19/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804222 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 02/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184154590 |
| Principal investigator 1 | ABBVIE INC. | $187.20 | 02/13/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202451397 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 02/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202450730 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 02/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202450734 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 02/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA CANCER CENTER | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202450739 |
| Principal investigator 1 | ABBVIE INC. | $52.00 | 02/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202450840 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300.00 | 02/10/2025 | Non-covered Recipient Entity The University of Arizona | Brightline-4 | No dispute reported | 06/30/2026 | 1220804240 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,850.00 | 02/10/2025 | Non-covered Recipient Entity The University of Arizona | Brightline-4 | No dispute reported | 06/30/2026 | 1220804242 |
| Principal investigator 1 | ABBVIE INC. | $2,283.79 | 02/06/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202448879 |
| Principal investigator 1 | ABBVIE INC. | $975.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202445361 |
| Principal investigator 1 | ABBVIE INC. | $780.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202445513 |
| Principal investigator 1 | ABBVIE INC. | $1,105.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202446597 |
| Principal investigator 1 | ABBVIE INC. | $2,119.00 | 02/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202443648 |
| Principal investigator 1 | BeiGene USA, Inc. | $928.00 | 01/28/2025 | Non-covered Recipient Entity University of Arizona | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies | No dispute reported | 06/30/2026 | 1190325866 |
| Principal investigator 1 | ABBVIE INC. | $3,499.65 | 01/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202441286 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $877.50 | 01/27/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804218 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,170.00 | 01/24/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804210 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $390.00 | 01/24/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804212 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,950.00 | 01/24/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804214 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $780.00 | 01/24/2025 | Non-covered Recipient Entity The University of Arizona | Phase II/III Brigimadlin in 1st L DD Liposarcoma | No dispute reported | 06/30/2026 | 1220804216 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 01/16/2025 | Non-covered Recipient Entity THE UNIVERSITY OF ARIZONA | M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | No dispute reported | 06/30/2026 | 1202439433 |
| Principal investigator 1 | Epizyme, Inc. | $250.00 | 01/09/2025 | Non-covered Recipient Entity Banner University Cancer Center | Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | No dispute reported | 06/30/2026 | 1184284530 |